Strategic Partnerships Plexium operates in targeted protein degradation with a robust DELTA Discovery platform and ultra-high throughput screening, suggesting high value in collaboration opportunities with CROs, academic consortia, and pharma partners pursuing novel degraders and molecular glues.

Clinical Expansion Recent leadership addition of a Chief Medical Officer and active presentations at AACR indicate a push toward clinical programs; prioritizing out-licensing or co-development deals for monovalent degraders and SMARCA2/IKZF2/CDK2 targets could accelerate commercial traction.

Targeted Pipeline Focus on hard-to-drug targets and first-in-class/best-in-class degraders presents a selling point for pharma companies seeking innovative modalities; identify strategic targets in oncology and related fields where degraders show promise.

Technology Enablement DELTA Discovery plus uHTS cell-based screening capability signals scalable discovery services and potential for sponsored research or paid discovery collaborations with larger biotech clients seeking rapid target validation.

Market Positioning With a mid-stage revenue profile and a growing clinical-stage pipeline, Plexium can be positioned as a high-velocity partner for biotech startups and mid-sized pharma seeking partnerships that leverage a nimble team and differentiated TPD platform.